C.T. Fitzpatrick
Vulcan Value Partners
Vulcan Value Partners CVS Health Corp stake
total: 270
Vulcan Value Partners CVS trades
- Total transactions:
- 23
- New positions:
- 3
- Sold out:
- 3
- Added:
- 9
- Reduced:
- 8
- Held since:
- 2016 Q4
- Held for:
- 18 quarters
- Latest activity:
- 2021 Q2
According to 2026 Q1 report, Vulcan Value Partners doesn't hold any CVS Health Corp (CVS) shares. To date, the estimated cost basis is nearly $70.99 for "buy" trades and estimated average "sell" price is $71.39. Vulcan Value Partners first purchased CVS in 2014 Q2, initially acquiring 475 shares. Vulcan Value Partners later completely sold out the position and invested in CVS Health Corp again in 2016 Q4. Since the initial investment in CVS Health Corp (CVS), Vulcan Value Partners has made 22 more transactions.
When did Vulcan Value Partners sell CVS Health Corp (CVS)?
Vulcan Value Partners sold off the entire CVS Health Corp (CVS) position in 2021 Q2.
When did Vulcan Value Partners buy CVS Health Corp (CVS)?
Vulcan Value Partners first invested in CVS Health Corp (CVS) in 2014 Q2 at the reported quarter-end price of $75.79 per share.
What's the cost basis of Vulcan Value Partners's CVS stake?
The estimated cost basis for CVS Health Corp (CVS) stake is around $70.99 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $70.99
- Weighted AVG sell price:
- $71.39
Vulcan Value Partners's historical trades in CVS Health Corp
23 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q2
|
0.00%
|
0
|
$75.19
|
|
-100% (-8,751)
|
-0%
|
|
2021 Q1
|
0.00%
|
8,751
|
$75.19
|
$658,000
|
-99.73% (-3,221,594)
|
-1.57%
|
|
2020 Q4
|
1.43%
|
$68.30
|
+5.85% (+178,500)
|
|||
|
2020 Q3
|
1.39%
|
$58.40
|
-30.39% (-1,332,165)
|
|||
|
2020 Q2
|
2.24%
|
$64.97
|
-17.42% (-924,705)
|
|||
|
2020 Q1
|
3.26%
|
$59.33
|
-20.55% (-1,373,177)
|
|||
|
2019 Q4
|
3.81%
|
$74.29
|
-23.68% (-2,073,020)
|
|||
|
2019 Q3
|
4.67%
|
$63.07
|
-1.92% (-171,719)
|
|||
|
2019 Q2
|
4.32%
|
$54.49
|
+12.17% (+968,162)
|
|||
|
2019 Q1
|
3.70%
|
$53.93
|
+56.77% (+2,881,953)
|
|||
|
2018 Q4
|
3.07%
|
$65.52
|
-12.64% (-734,563)
|
|||
|
2018 Q3
|
3.34%
|
$78.72
|
-38.98% (-3,711,665)
|
|||
|
2018 Q2
|
4.74%
|
$64.35
|
+2.34% (+217,406)
|
|||
|
2018 Q1
|
4.66%
|
$62.21
|
+5.27% (+465,460)
|
|||
|
2017 Q4
|
5.25%
|
$72.50
|
+1.19% (+103,776)
|
|||
|
2017 Q3
|
6.08%
|
$81.32
|
+13.61% (+1,046,719)
|
|||
|
2017 Q2
|
5.51%
|
$80.46
|
+1.36% (+102,834)
|
|||
|
2017 Q1
|
5.14%
|
$78.50
|
+42.22% (+2,252,242)
|
|||
|
2016 Q4
|
3.75%
|
$78.91
|
new
|
|||
|
2016 Q1
|
0.00%
|
$97.67
|
-100% (-2,150)
|
|||
|
2015 Q4
|
0.00%
|
$97.67
|
new
|
|||
|
2014 Q3
|
0.00%
|
$75.79
|
-100% (-475)
|
|||
|
2014 Q2
|
0.00%
|
$75.79
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.